Modality
mAb (human IgG1)
Mechanism
TNF-α inhibition (soluble + transmembrane)
Targets
TNF
Storage
refrigerated 2–8 °C
Approved
plaque psoriasis — FDA 2008 · hidradenitis suppurativa — FDA 2015 · psoriatic arthritis — FDA 2005 · rheumatoid arthritis — FDA 2002 · Crohn's disease — FDA 2007
In trial
—
Black-box warnings
serious infections (TB reactivation, invasive fungal); lymphoma/malignancy
Pregnancy
limited human data; IgG1 crosses placenta in 3rd trimester
Monitoring
baseline TB + HBV/HCV screen, periodic CBC / LFT
Sources
Last verified
2026-04-23
Mechanism of action
Humira label (FDA, 2024)drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug
Monitoring & workup
Baseline workup
- •TB IGRA (or PPD) + CXR
- •HBV sAg + core Ab + surface Ab; HCV Ab
- •CBC with differential
- •CMP
- •Update age-appropriate vaccines including live vaccines before start
Ongoing monitoring
- •Symptom-driven; no routine labs
- •Annual TB screening if high exposure risk
- •Monitor for serious infection, reactivation (TB/HBV), demyelinating disease, paradoxical psoriasis